Compared with sitagliptin @ mg , canagliflozin @ mg demonstrated superior diabetes-related quality measure attainment , including glycemic , BP , and weight-related quality measures ; there was no difference in LDL-C quality measure attainment between either dosage of canagliflozin and the @-mg dosage of sitagliptin .